China approves country's first COVID-19 antibody drug, developed by Tsinghua research team


Key Topics in this News Article:

News Snapshot:

Photo provided to People's Daily A Chinese research team has developed an "antibody cocktail therapy" that can fight SARS-CoV-2. The antibody cocktail made of two monoclonal antibodies Brii-196 and Brii-198 has shown an efficacy of 80 percent in cutting hospitalizations and deaths among high-risk groups in multicenter randomized clinical trials. The treatment was jointly developed by a research team led by Zhang Linqi, a professor at School of Medicine of Tsinghua University, the Third People's Hospital of Shenzhen, Guangdong province, and Brii Biosciences. Zhang has devoted 30 years to studying HIV-1 pathogenesis and vaccine development, and also emerging and re-emerging...